Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Amortizatization of Intangibles (2016 - 2020)

GT Biopharma (GTBP) has disclosed Amortizatization of Intangibles for 11 consecutive years, with $317000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Amortizatization of Intangibles rose 487.04% to $317000.0 in Q4 2020 year-over-year; TTM through Sep 2021 was $317000.0, a 487.04% increase, with the full-year FY2023 number at $112000.0, up 17.89% from a year prior.
  • Amortizatization of Intangibles was $317000.0 for Q4 2020 at GT Biopharma, up from -$1000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $3.4 million in Q3 2017 to a low of -$1.6 million in Q4 2016.
  • A 5-year average of $525062.5 and a median of $165500.0 in 2019 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: crashed 225.31% in 2016, then skyrocketed 487.04% in 2020.
  • GT Biopharma's Amortizatization of Intangibles stood at -$1.6 million in 2016, then skyrocketed by 107.57% to $123000.0 in 2017, then soared by 2066.67% to $2.7 million in 2018, then crashed by 97.97% to $54000.0 in 2019, then surged by 487.04% to $317000.0 in 2020.
  • Per Business Quant, the three most recent readings for GTBP's Amortizatization of Intangibles are $317000.0 (Q4 2020), -$1000.0 (Q3 2020), and $1000.0 (Q2 2020).